How to use COVID-19 antiviral drugs in patients with chronic kidney disease
Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid), Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus Disease (COVID)-19. Although chronic kidney disease is a highly prevalent risk factor for severe and fatal COVID-19, most c...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1053814/full |
| _version_ | 1828038337527545856 |
|---|---|
| author | Ajinath Kale Vishwadeep Shelke Neha Dagar Hans-Joachim Anders Anil Bhanudas Gaikwad |
| author_facet | Ajinath Kale Vishwadeep Shelke Neha Dagar Hans-Joachim Anders Anil Bhanudas Gaikwad |
| author_sort | Ajinath Kale |
| collection | DOAJ |
| description | Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid), Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus Disease (COVID)-19. Although chronic kidney disease is a highly prevalent risk factor for severe and fatal COVID-19, most clinical trials with these drugs excluded patients with impaired kidney function. Advanced CKD is associated with a state of secondary immunodeficiency (SIDKD), which increases the susceptibility to severe COVID-19, COVID-19 complications, and the risk of hospitalization and mortality among COVID-19 patients. The risk to develop COVID-19 related acute kidney injury is higher in patients with precedent CKD. Selecting appropriate therapies for COVID-19 patients with impaired kidney function is a challenge for healthcare professionals. Here, we discuss the pharmacokinetics and pharmacodynamics of COVID-19-related antiviral drugs with a focus on their potential use and dosing in COVID-19 patients with different stages of CKD. Additionally, we describe the adverse effects and precautions to be taken into account when using these antivirals in COVID-19 patients with CKD. Lastly, we also discuss about the use of monoclonal antibodies in COVID-19 patients with kidney disease and related complications. |
| first_indexed | 2024-04-10T16:25:31Z |
| format | Article |
| id | doaj.art-263ec1b938684aa58e5770dfa5228be5 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T16:25:31Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-263ec1b938684aa58e5770dfa5228be52023-02-09T06:19:04ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-02-011410.3389/fphar.2023.10538141053814How to use COVID-19 antiviral drugs in patients with chronic kidney diseaseAjinath Kale0Vishwadeep Shelke1Neha Dagar2Hans-Joachim Anders3Anil Bhanudas Gaikwad4Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, IndiaLaboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, IndiaLaboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, IndiaDivision of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University Munich, Munich, Germany.Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, IndiaAntiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid), Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus Disease (COVID)-19. Although chronic kidney disease is a highly prevalent risk factor for severe and fatal COVID-19, most clinical trials with these drugs excluded patients with impaired kidney function. Advanced CKD is associated with a state of secondary immunodeficiency (SIDKD), which increases the susceptibility to severe COVID-19, COVID-19 complications, and the risk of hospitalization and mortality among COVID-19 patients. The risk to develop COVID-19 related acute kidney injury is higher in patients with precedent CKD. Selecting appropriate therapies for COVID-19 patients with impaired kidney function is a challenge for healthcare professionals. Here, we discuss the pharmacokinetics and pharmacodynamics of COVID-19-related antiviral drugs with a focus on their potential use and dosing in COVID-19 patients with different stages of CKD. Additionally, we describe the adverse effects and precautions to be taken into account when using these antivirals in COVID-19 patients with CKD. Lastly, we also discuss about the use of monoclonal antibodies in COVID-19 patients with kidney disease and related complications.https://www.frontiersin.org/articles/10.3389/fphar.2023.1053814/fullCOVID-19antiviralschronic kidney diseaseclinical trialspharmacokineticspharmacodynamics |
| spellingShingle | Ajinath Kale Vishwadeep Shelke Neha Dagar Hans-Joachim Anders Anil Bhanudas Gaikwad How to use COVID-19 antiviral drugs in patients with chronic kidney disease Frontiers in Pharmacology COVID-19 antivirals chronic kidney disease clinical trials pharmacokinetics pharmacodynamics |
| title | How to use COVID-19 antiviral drugs in patients with chronic kidney disease |
| title_full | How to use COVID-19 antiviral drugs in patients with chronic kidney disease |
| title_fullStr | How to use COVID-19 antiviral drugs in patients with chronic kidney disease |
| title_full_unstemmed | How to use COVID-19 antiviral drugs in patients with chronic kidney disease |
| title_short | How to use COVID-19 antiviral drugs in patients with chronic kidney disease |
| title_sort | how to use covid 19 antiviral drugs in patients with chronic kidney disease |
| topic | COVID-19 antivirals chronic kidney disease clinical trials pharmacokinetics pharmacodynamics |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1053814/full |
| work_keys_str_mv | AT ajinathkale howtousecovid19antiviraldrugsinpatientswithchronickidneydisease AT vishwadeepshelke howtousecovid19antiviraldrugsinpatientswithchronickidneydisease AT nehadagar howtousecovid19antiviraldrugsinpatientswithchronickidneydisease AT hansjoachimanders howtousecovid19antiviraldrugsinpatientswithchronickidneydisease AT anilbhanudasgaikwad howtousecovid19antiviraldrugsinpatientswithchronickidneydisease |